CA-125


Also found in: Wikipedia.

CA-125

Abbreviation for cancer antigen 125 and the test for it. See: cancer antigen 125 test.

MUC16

A gene on chromosome 19p13.2 which encodes a protein that provides a protective lubricating barrier against particles and infectious agents at mucosal surfaces. It is more commonly known as CA125, and is a highly characteristic marker of ovarian carcinomas.

CA-125

A cell surface glycoprotein expressed on the cell membrane of normal ovarian tissue, ovarian, cervical, endometrium, GI tract, and breast CAs; rising levels indicate a poor prognosis, but low levels are of little clinical utility; CA-125 may also be ↑ in liver disease, acute pancreatitis, renal failure, occasionally in normal ♀, lymphoma
References in periodicals archive ?
A blood test can be carried out to identify a blood protein that is elevated in many cases of ovarian cancer, called CA-125.
The blood test measures levels of an ovarian cancer marker called CA-125--but about 20 percent of women with ovarian cancer don't have elevated CA-125 levels, while about three percent of women who do have high levels don't have ovarian cancer, since CA-125 also can be raised by other conditions.
4) However, due to the performance limitations of the standard tools and aims to improve the sensitivity, specificity, and positive predictive value of tumor markers in ovarian cancer, a number of new biomarkers have been studied and evaluated to be used in combination with CA-125.
CA-125 level before surgery was within normal limits.
CA-125 was interpreted with the risk of ovarian cancer algorithm, which considers changes over time, with increases indicating potential problems.
Keywords: PFTC (Primary fallopian tube carcinoma), CA-125 levels, EOC (Epithelial ovarian cancer), BRCA-1 and BRCA-2 mutations.
The Meigs' syndrome can be easily misdiagnosed as malignant ovarian tumors because of accompanying ascites with an increased serum CA-125 level.
The study compared clinical outcomes and costs using OVA1 versus the off-label but commonly used CA-125 (CA 125-II), an ovarian cancer biomarker, or current gynecologic best-practice care known as Dearking-modified ACOG guidelines (mod-ACOG).
The serum CA-125 level is not specific and does not always increase (6).
Unfortunately the CA-125 test has not proven effective for ovarian cancer screening in asymptomatic women.
The results showed that in the rats from Groups A, C, D and E, the serum CA-125 levels, COX-2 mRNA expression in the ectopic endometrium and the IL-18 levels in the peritoneal fluids were significantly lower than those of Group B (P (less than) 0.